Odanacatib

Drug Profile

Odanacatib

Alternative Names: MK-0822; MK-822

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celera Group
  • Developer Banyu; Merck & Co
  • Class Amides; Biphenyl compounds; Cyclopropanes; Nitriles; Osteoporosis therapies; Small molecules; Sulfones
  • Mechanism of Action Bone resorption factor inhibitors; Cathepsin K inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bone metastases; Corticosteroid-induced osteoporosis; Male osteoporosis; Osteoarthritis; Osteoporosis; Postmenopausal osteoporosis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 26 Sep 2016 Merck Sharp & Dohme terminates a phase I trial in Corticosteroid-induced osteoporosis (In adolescents, Prevention, In adults) in USA, United Kingdom, Italy and Finland (NCT01630616, EudraCT2012-003414-14)
  • 16 Sep 2016 Efficacy and adverse events data from an extension study of the phase III LOFT trial in Osteoporosis presented at the 38th Annual Meeting of the American Society for Bone and Mineral Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top